- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Uncontrolled severe asthma
- Meeting Date: March 2024
- Public Summary Document (PSD) March 2024 PBAC Meeting - (PDF 605KB)
- Public Summary Document (PSD) March 2024 PBAC Meeting - (Word 159KB)
Mepolizumab – March 2024
Mepolizumab: Powder for injection 100 mg, Injection 100 mg in 1 mL single dose pre filled pen: Nucala®
Last updated
30 May 2025